Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.

JTO Clin Res Rep · 2022 · PMC9234704 · PMID 35769388

Europe PMC DOI

hedged sentence

0.0706

closest p · 1.4× alpha

0.0706

boldest claim

The sentences

did not reach statistical significancep = 0.0706so close (0.05 < p ≤ 0.1)

The median OS was longer in the ICI/Chemo group than in the pembrolizumab group, but the difference did not reach statistical significance (22.7 mo versus 19.9 mo, p = 0.0706) ( Fig. 2 B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.